Annelies Verbon Selected Research

Mycetoma

6/2022	Eumycetoma causative agents are inhibited in vitro by luliconazole, lanoconazole and ravuconazole.
2/2022	Inhibiting DHN- and DOPA-melanin biosynthesis pathway increased the therapeutic value of itraconazole in Madurella mycetomatis infected Galleria mellonella.
1/2022	Identifying novel drugs with new modes of action for neglected tropical fungal skin diseases (fungal skinNTDs) using an Open Source Drug discovery approach.
1/2022	Screening the pandemic response box identified benzimidazole carbamates, Olorofim and ravuconazole as promising drug candidates for the treatment of eumycetoma.
1/2022	The developed molecular biological identification tools for mycetoma causative agents: An update.
1/2021	Melanin production in coelomycetous agents of black grain eumycetoma.
1/2020	Madurella mycetomatis, the main causative agent of eumycetoma, is highly susceptible to olorofim.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Annelies Verbon Research Topics

Disease

29	Infections 01/2022 - 08/2002
8	HIV Infections (HIV Infection) 06/2022 - 04/2002
7	Mycetoma 06/2022 - 01/2020
5	Urinary Tract Infections (Urinary Tract Infection) 01/2020 - 10/2007
5	Legionnaires' Disease (Legionnaire's Disease) 01/2018 - 08/2002
5	Tuberculosis (Tuberculoses) 10/2017 - 01/2002
5	Sepsis (Septicemia) 10/2013 - 07/2009
4	Acquired Immunodeficiency Syndrome (AIDS) 01/2015 - 04/2007
4	Pneumonia (Pneumonitis) 12/2004 - 08/2002
3	Malaria 01/2022 - 12/2016
3	Inflammation (Inflammations) 01/2020 - 10/2019
3	Neutropenia 02/2016 - 01/2014
3	Abscess 01/2014 - 01/2013
3	Endotoxemia 07/2003 - 04/2002
2	COVID-19 11/2022 - 01/2020
2	Fibrosis (Cirrhosis) 01/2020 - 01/2019
2	Communicable Diseases (Infectious Diseases) 11/2019 - 01/2019
2	Cardiovascular Diseases (Cardiovascular Disease) 01/2019 - 04/2015
2	Aspergillosis 09/2018 - 07/2015
2	Kaposi Sarcoma (Kaposi's Sarcoma) 11/2016 - 11/2013
2	Dyslipidemias (Dyslipidemia) 04/2015 - 01/2014
2	Diverticulitis 01/2013 - 01/2013
1	Neglected Diseases 01/2022
1	Chromoblastomycosis (Chromomycosis) 01/2022
1	Dermatomycoses 01/2022
1	Sporotrichosis 01/2022
1	Hyperthermia 12/2021
1	Mycoses (Diseases, Fungus) 01/2021
1	Respiratory Distress Syndrome (Acute Respiratory Distress Syndrome) 01/2020
1	Acute Lung Injury 01/2020
1	Rare Diseases (Rare Disease) 01/2020
1	Invasive Fungal Infections 01/2020
1	Uterine Cervical Neoplasms (Cancer of the Cervix) 01/2020
1	Meningoencephalitis 01/2020
1	Viremia 01/2019
1	Persistent Infection 01/2019
1	Graft vs Host Disease (Graft-Versus-Host Disease) 09/2018
1	Peritonitis 05/2018
1	Bites and Stings (Sting) 01/2018
1	Headache (Headaches) 12/2017

Drug/Important Bio-Agent (IBA)

17	Anti-Bacterial Agents (Antibiotics)IBA 01/2022 - 01/2011
6	Pharmaceutical PreparationsIBA 06/2022 - 01/2014
5	CytokinesIBA 01/2020 - 08/2002
4	Antifungal AgentsIBA 06/2022 - 01/2020
4	Inosine TriphosphataseIBA 01/2018 - 01/2012
3	AntigensIBA 11/2019 - 12/2002
2	ER 30346 (ravuconazole)IBA 06/2022 - 01/2022
2	Melanins (Melanin)IBA 02/2022 - 01/2021
2	olorofimIBA 01/2022 - 01/2020
2	Itraconazole (Sporanox)FDA LinkGeneric 01/2022 - 01/2020
2	CarbamatesIBA 01/2022 - 01/2022
2	benzimidazoleIBA 01/2022 - 01/2022
2	Viral RNAIBA 11/2021 - 01/2021
2	Interleukin-12 (IL 12)IBA 12/2019 - 08/2012
2	Antiviral Agents (Antivirals)IBA 11/2019 - 01/2019
2	dolutegravirIBA 10/2019 - 12/2017
2	Biomarkers (Surrogate Marker)IBA 12/2016 - 07/2009
2	Proteins (Proteins, Gene)FDA Link 01/2012 - 11/2005
2	Toll-Like Receptor 4IBA 02/2005 - 08/2002
2	Toll-Like Receptors (Toll-Like Receptor)IBA 12/2004 - 11/2003
2	LipopolysaccharidesIBA 08/2002 - 04/2002
1	Indicators and Reagents (Reagents)IBA 11/2022
1	latoconazole (lanoconazole)IBA 06/2022
1	luliconazoleIBA 06/2022
1	Terbinafine (Lamisil)FDA LinkGeneric 01/2022
1	FenbendazoleIBA 01/2022
1	Biological ProductsIBA 01/2022
1	Neutralizing AntibodiesIBA 11/2021
1	1- acetyl- 1,2,3,3a,8,8a- hexahydro- 8a- hydroxy- 5- methoxypyrrolo(2,3- b)indole (CHMI)IBA 01/2020
1	Valsartan (Vals)FDA Link 01/2020
1	Transforming Growth Factor beta (TGF-beta)IBA 01/2020
1	Angiotensin IIIBA 01/2020
1	Fatty Acids (Saturated Fatty Acids)IBA 01/2020
1	Alanine Transaminase (SGPT)IBA 11/2019
1	AerosolsIBA 11/2019
1	LipidsIBA 10/2019
1	RNA (Ribonucleic Acid)IBA 01/2019
1	InterferonsIBA 01/2019
1	abacavir (Ziagen)FDA Link 01/2019
1	SphingomyelinsIBA 11/2018
1	Triglycerides (Triacylglycerol)IBA 11/2018
1	Tryptophan (L-Tryptophan)FDA Link 11/2018
1	NitrogenIBA 11/2018
1	Biogenic Amines (Biogenic Amine)IBA 11/2018
1	Phospholipids (Phosphatides)FDA LinkGeneric 11/2018
1	AzolesIBA 09/2018
1	QuinolonesIBA 05/2018
1	Bacterial DNAIBA 01/2018
1	ametantrone (HAQ)IBA 01/2018
1	cyclic guanosine monophosphate-adenosine monophosphateIBA 01/2018
1	Ciprofloxacin (Cipro)FDA LinkGeneric 01/2017
1	Antitubercular AgentsIBA 01/2017
1	Angiopoietin-2IBA 12/2016
1	Rosiglitazone (Avandia)FDA Link 12/2016

Therapy/Procedure

18	Therapeutics 06/2022 - 12/2002
9	Highly Active Antiretroviral Therapy (HAART) 11/2021 - 07/2009
2	Art Therapy 06/2022 - 01/2020
1	Continuity of Patient Care 11/2022
1	Treatment Delay 01/2019
1	Antibiotic Prophylaxis 05/2018